Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cassava Sciences Inc (SAVA)

Cassava Sciences Inc (SAVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 886,543
  • Shares Outstanding, K 43,246
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,220 K
  • 60-Month Beta -0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.50
Trade SAVA with:

Options Overview Details

View History
  • Implied Volatility 83.46% ( +83.46%)
  • Historical Volatility 89.00%
  • IV Percentile 69%
  • IV Rank 29.70%
  • IV High 129.23% on 10/17/23
  • IV Low 64.13% on 03/27/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 2,220
  • Volume Avg (30-Day) 4,943
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 100,264
  • Open Int (30-Day) 85,653

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.43 +5.74%
on 04/16/24
26.68 -22.96%
on 04/11/24
+0.74 (+3.74%)
since 03/22/24
3-Month
18.18 +13.04%
on 03/11/24
27.18 -24.38%
on 01/24/24
-5.47 (-21.02%)
since 01/23/24
52-Week
12.32 +66.80%
on 10/13/23
32.10 -35.98%
on 12/12/23
-2.95 (-12.55%)
since 04/21/23

Most Recent Stories

More News
Is There Any Hope for Cassava Sciences Stock?

Battered by controversy, this company will need to show real results to prosper.

SAVA : 20.55 (+0.24%)
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street

Wall Street analysts foresee up to 316% upside in three fast-paced companies in the new year.

COMP : 3.41 (+2.71%)
PLUG : 2.59 (+4.02%)
LXRX : 1.6100 (-5.85%)
SAVA : 20.55 (+0.24%)
Why Cassava Sciences Stock Zoomed 21% Higher This Week

The company has chosen an offbeat way to keep its investors sweet.

SAVA : 20.55 (+0.24%)
Why Cassava Sciences Stock Soared Today

Investors cheered the arrival of a trio of new board members.

SAVA : 20.55 (+0.24%)
1 Big Red Flag to Fear When a Stock Is Down

Playing the blame game does not make for an effective turnaround strategy.

SAVA : 20.55 (+0.24%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such...

SAVA : 20.55 (+0.24%)
Why Cassava Sciences Stock Is Tanking Today

Investors are worried about a leaked report related to alleged data manipulation for Cassava's Alzheimer's disease treatment candidate.

SAVA : 20.55 (+0.24%)
Why Shares of Cassava Sciences Soared This Week

Cassava bounced back from hitting a 52-week low to start the week.

SAVA : 20.55 (+0.24%)
Why Shares of Cassava Sciences Are Dropping Wednesday

The company announced phase 3 trial results for its lead Alzheimer's therapy.

LLY : 745.69 (+1.96%)
SAVA : 20.55 (+0.24%)
Why Shares of Cassava Sciences Jumped This Week

Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.

SAVA : 20.55 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 21.92
2nd Resistance Point 21.56
1st Resistance Point 21.06
Last Price 20.55
1st Support Level 20.20
2nd Support Level 19.84
3rd Support Level 19.34

See More

52-Week High 32.10
Fibonacci 61.8% 24.54
Fibonacci 50% 22.21
Last Price 20.55
Fibonacci 38.2% 19.88
52-Week Low 12.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar